Search
for
Sort by
Research 421–450 of 773
- Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Oral Tofacitinib in Refractory Pediatric Alopecia Areata
- Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata
- Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
- Surgical Approaches for Repigmenting Vitiligo 2.0
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- The influence of interferon on healthy and diseased skin
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Alopecia Areata: An Update on Treatment Options for Children
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Immunomodulatory Potential and Biocompatibility of Chitosan–Hydroxyapatite Biocomposites for Tissue Engineering
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches
- Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Selection signatures of wool color in Gangba sheep revealed by genome-wide SNP discovery